DETROIT – Beaumont Health has launched a new clinical study aimed at treating COVID-19 patients with two common drugs – naltrexone and ketamine.
Beaumont says it received FDA approval to operate the new clinical trial at Beaumont Hospital in Royal Oak.
The study, called “SINK COVID-19,” or the Study of Immunomodulation using Naltrexone and Ketamine for COVID-19, is a randomized study for patients 18 and older.
Beaumont researchers say they are hopeful the two drugs can lessen the severity of COVID-19 symptoms by reducing the early and later side effects of the virus.
Related: Beaumont Health launches study on coronavirus (COVID-19) antibodies
“There is an urgent need to develop new treatments for COVID-19 using easily available and affordable medications,” said Dr. Matthew Sims, director, Infectious Disease Research, Beaumont Health and study principal investigator. “Ideal new treatments for COVID-19 would help halt the progression of the disease in patients with mild cases prior to the need for ventilators, and provide